DIM
ADCT icon

DLK Investment Management’s ADC Therapeutics ADCT Stock Holding History

DLK Investment Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$37.2K Sell
30,467
-2,688
-8% -$3.14K 0.01% 92
2026
Q2 		$105K Buy
33,155
+7,850
+31% +$22.9K 0.04% 80
2026
Q1 		$94.9K Hold
25,305
– – 0.04% 82
2025
Q4 		$89.3K Hold
25,305
– – 0.03% 81
2025
Q3 		$101K Hold
25,305
– – 0.04% 79
2025
Q2 		$67.8K Sell
25,305
-1,500
-6% -$3.15K 0.03% 77
2025
Q1 		$37.8K Buy
26,805
+1,000
+4% +$1.7K 0.02% 77
2024
Q4 		$51.4K Sell
25,805
-7,350
-22% -$19.2K 0.02% 78
2024
Q3 		$104K Hold
33,155
– – 0.04% 89
2024
Q2 		$105K Hold
33,155
– – 0.04% 83
2024
Q1 		$149K Hold
33,155
– – 0.06% 79
2023
Q4 		$55K Buy
+33,155
New +$30.6K 0.03% 86

Other funds holding ADCT

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

DLK Investment Management's ADCT Position: Q3 2026 in Review

DLK Investment Management reduced its ADC Therapeutics (ADCT) stake by 8.1% in Q3 2026, selling an estimated $3.14K and leaving 30,467 shares worth $37.2K. The position accounts for 0.01% of the portfolio, ranked #92.

DLK Investment Management first reported a position in ADCT in Q4 2023 and has held it in 12 quarters since. The position peaked at $149K in Q1 2024. 4 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • DLK Investment Management held 30,467 shares of ADC Therapeutics worth $37.2K as of Q3 2026.
  • DLK Investment Management sold 2,688 ADC Therapeutics shares in Q3 2026, an estimated $3.14K.
  • ADC Therapeutics made up 0.01% of DLK Investment Management's portfolio in Q3 2026, its #92 holding.
  • DLK Investment Management first reported a position in ADC Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • DLK Investment Management's ADC Therapeutics position peaked at $149K in Q1 2024.
  • 4 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on DLK Investment Management's 13F filing for Q3 2026, filed 9 Oct 2026.